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Abstract
The inherited metabolic disease propionic acidemia (PA) can result from mutations in either of the genes PCCA or PCCB,
which encode the K and L subunits, respectively, of the mitochondrial enzyme propionyl CoA-carboxylase. In this work we
have analyzed the molecular basis of PCCA gene defects, studying mRNA levels and identifying putative disease causing
mutations. A total of 10 different mutations, none predominant, are present in a sample of 24 mutant alleles studied. Five
novel mutations are reported here for the first time. A neutral polymorphism and a variant allele present in the general
population were also detected. To examine the effect of a point mutation (M348K) involving a highly conserved residue, we
have carried out in vitro expression of normal and mutant PCCA cDNA and analyzed the mitochondrial import and stability
of the resulting proteins. Both wild-type and mutant proteins were imported into mitochondria and processed into the
mature form with similar efficiency, but the mature mutant M348K protein decayed more rapidly than did the wild-type,
indicating a reduced stability, which is probably the disease-causing mechanism. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Propionic acidemia (PA) is the most frequent in-
born error of organic acids metabolism in humans,
caused by a de¢ciency of the mitochondrial biotin-
dependent enzyme propionyl-CoA carboxylase
(PCC; EC 6.4.1.3) [1]. Native PCC probably exists
as a dodecamer of K and L subunits, encoded by the
PCCA and PCCB genes, respectively. Enzyme de¢-
ciency can result from mutations in either the PCCA
or the PCCB genes, de¢ning the two major comple-
mentation groups, pccA and pccBC. The disease, in-
herited as an autosomal recessive trait, shows con-
siderable phenotypical heterogeneity not correlated
with complementation group assignment. The clini-
cal manifestations of PCC de¢ciency range from life-
threatening ketoacidosis in neonates to mild, late-on-
set presentations including developmental retarda-
tion with recurrent acidotic episodes.
Full-length cDNAs for the K and L subunits have
been cloned and sequenced [2^4]. The PCCA cDNA
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contains an open reading frame of 2109 nucleotides
coding for 703 amino acids and the PCCB cDNA
contains an open reading frame of 1617 nucleotides
encoding a 539-amino-acid polypeptide. Both sub-
units are initially synthesized as larger precursors
with NH2-terminal leader sequences, and are subse-
quently transported across both mitochondrial mem-
branes, cleaved to their mature size and assembled
[5,6]. The mature K subunit is 70 kDa and contains
the biotin binding site, as well as the conserved ATP
binding site and biotin carboxylase domain.
Northern blot analyses in patients’ cell lines
showed that in most pccA mutants K-subunit
mRNA was absent, while L-subunit mRNA was nor-
mal. In contrast, both mRNAs were present in mu-
tants of the pccBC group [7,8]. These results may
account for the fact that the identi¢cation of the
mutations causing PA has been focused primarily
on the PCCB gene, sequencing reverse transcrip-
tion^polymerase chain reaction (RT^PCR) products.
As a consequence, many di¡erent PCCB gene muta-
tions have been reported, both in Caucasians [9,10]
and in Orientals [11,12]. Recently, our group has
described the exonic structure of the PCCB gene
and the detailed mutational spectrum found in Span-
ish and Latin-American PA patients [13]. In contrast,
genetic analyses of the K-subunit-de¢cient patients
has progressed more slowly, also hampered by the
lack of information of the PCCA gene structure. In
Spanish patients we have recently identi¢ed three
mutations a¡ecting splicing [14].
In this work we have analyzed the molecular basis
of PA in 12 pccA patients, showing normal K-
mRNA levels in seven of them and characterizing
approximately 65% of the total mutant alleles. Five
novel mutations are reported here for the ¢rst time.
The mutational spectrum includes two nonsense mu-
tations, six missense and three splice mutations. No
predominant mutations were found, suggesting there
is a high heterogeneity underlying K-subunit defects
in PA. We have analyzed the e¡ect of the M348K
mutation, located within the highly conserved biotin
carboxylase domain, on the in vitro biogenesis, mi-
tochondrial import and degradation, observing de-
creased stability of the mutant protein compared to
the wild-type. We suggest that a similar mechanism
may underlie the e¡ect of other missense mutations
which result in a non-functional PCC K subunit.
2. Patients and methods
A total of 12 unrelated PA patients with K-subunit
de¢ciency were included in this study, 11 from Spain
and one from Brazil. In two patients there were no
samples available for RNA analysis so only studies
with genomic DNA could be performed. The pa-
tients were diagnosed on the basis of the clinical
symptoms and biochemical analysis and de¢cient
PCC activity in lymphocytes and/or cultured ¢bro-
blasts (6 4% control values). The patients were
shown to have no functional K protein by [3H]biotin
labeling of cultured ¢broblasts and no immunoreac-
tive L-subunit by Western blot analysis. Consanguin-
ity among parents was documented for four of the
patients.
Skin ¢broblasts from propionic acidemia patients,
parents and controls were cultured according to
standard procedures in MEM supplemented with
1% glutamine, 10% fetal calf serum and antibiotics,
in a humidi¢ed atmosphere containing 5% CO2.
Total RNA was isolated from cultured skin ¢bro-
blasts by the guanidium isothiocyanate method [15].
Northern blot analysis was carried out according to
standard procedures using 20 Wg of total RNA trans-
ferred to nylon membranes (GeneScreen Plus, Du-
pont). The K- and L-subunit cDNAs were used as
probes, puri¢ed from vectors pCMVA35-3 and
pRCCMVB52, respectively, both of them kindly pro-
vided by Dr. D. Leclerc and Prof. R.A. Gravel. An
K-tubulin cDNA probe cloned in pUC8 was used as
control of mRNA levels. The probes were labeled
with [32P]dCTP using the Random Primer kit from
Stratagene.
RT^PCR was performed with 1 Wg total RNA and
primers APA1 to APA14 (Table 1), by use of the
Access RT^PCR System from Promega, according
to the instructions of the manufacturer. Seven over-
lapping fragments covering the whole coding se-
quence of the PCCA gene were thus ampli¢ed.
Isolation of genomic DNA was carried out as pre-
viously described [16]. Ampli¢cation of exonic frag-
ments from genomic DNA was performed with
standard PCR conditions using intronic primers,
their sequences kindly provided by Prof. R.A. Gravel
and E. Campeau.
For direct sequencing exonic PCR products were
separated by agarose (4% Nusieve) electrophoresis,
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puri¢ed using the Wizard PCR preps kit (Promega)
and cycle sequenced using the fmol DNA sequencing
kit (Promega), using nested intronic primers £uores-
cently labeled. RT^PCR products were sequenced
with the primers used for ampli¢cation, also £uores-
cently labeled. Sequences were analyzed on an auto-
mated DNA sequencer (ALF Express, Pharmacia).
Restriction analysis, direct or after creating the
restriction site in the ampli¢cation (ACRS) was
used to con¢rm and/or screen for the following mu-
tations: R52W (AvaI, ACRS), A113T (AluI), R288X
(HinfI), M348K (BstYI), G606R (AvaII, ACRS).
I450V was screened for by restriction analysis with
RsaI after ACRS.
For in vitro transcription and translation, PCCA
cDNA was cloned in the NotI site of the pGEM-
11Zf(+) vector (Promega). To introduce the
M348K mutation, the Gene Editor in vitro Site-Di-
rected Mutagenesis System (Promega) was used, with
the oligonucleotide M348K (5P-ATGCCAGGAAAA-
GATCCGTGTTG-3P). One Wg of the resulting plas-
mids, normal and mutant, were used with the TnT
Coupled Transcription/Translation kit (Promega) in
the presence of [35S]methionine^cysteine, following
the manufacturer’s protocol. Rat liver mitochondria
were prepared according to previously described
methods [17] and were used at 20 mg/ml in HMS
bu¡er (2 mM Hepes (pH 7.4), 220 mM D-mannitol,
70 mM sucrose). Mitochondrial import was carried
out with equal volumes of translation product and
mitochondria, incubated at 30‡C for 40 min. The
mitochondrial pellet was then separated from the
supernatant by centrifugation, washed twice with
HMS bu¡er, resuspended in the same bu¡er and
both the ¢rst supernatant and the mitochondria
were incubated with trypsin at 20 Wg/ml at 4‡C for
15 min, followed by an additional 10-min incubation
with 0.2 mg/ml soybean trypsin inhibitor. Samples
were then boiled with electrophoresis sample bu¡er,
and analyzed by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) and £uorog-
raphy using Amplify reactive (Amersham). To asses
the intramitochondrial stability of normal and mu-
tant proteins, after 40 min incubation with the trans-
lation products, the mitochondria were washed twice
with HMS bu¡er, resuspended in the same bu¡er
and further incubated at 37‡C, removing aliquots
at di¡erent time points up to 24 h. The radioactive
proteins were visualized after SDS^PAGE and £uo-
rography. The bands were quantitated by laser den-
sitometry.
3. Results
3.1. Northern blot analysis
Seven cell lines of pccA de¢cient patients were
examined and in all of them a single band of 2.8 kb
corresponding to K-PCC mRNA was easily detect-
Table 1
Primers used for the ampli¢cation by RT^PCR of the total PCCA cDNA sequence in seven overlapping fragments
cDNA fragment Oligos PCR (bp)
1 (nt 343 to 343) APA1 5P TGGTCGCTGCCGGACGGCGT 3P 386
APA2 5P GTACAGATTGGGCCCTGGTT 3P
2 (nt 283 to 652) APA3 5P AGCTACCTCAACATGGATGC 3P 370
APA4 5P TAAAACCATCCCTGGTGTCT 3P
3 (nt 603 to 952) APA5 5P GAAAGGCATGCGATTGCTT 3P 350
APA6 5P TCTTAGAGTCCACAAGGAAC 3P
4 (nt 886 to 1310) APA7 5P GTAGCTCTTGCCAGAGCAGT 3P 425
APA8 5P GCATCTGCCATTCTCTTCAG 3P
5 (nt 1223 to 1602) APA9 5P GTGGCATCCAACCAGGAAGT 3P 380
APA10 5P CCAGTTGGCTATGTCTGGTT 3P
6 (nt 1527 to 1894) APA11 5P GGCATTCCAGTTAAGAGCAC 3P 368
APA12 5P CCTCAGTCACTTTTTCCAGC 3P
7 (nt 1843 to 2222) APA13 5P ACCAGACTTGCCGCAGAATT 3P 380
APA14 5P AAACGTAGCTGCACAGGGGT 3P
Nucleotide (nt) numbering starts at the ATG translation initiation codon.
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able, and the mRNA size and amount were indistin-
guishable from that in controls. Fig. 1 shows the
result of the Northern blot analysis in six of the
patients. L-Chain mRNA was also normal, and as
described previously [7], using the L probe, two spe-
cies are detected, a major one at 2 kb and a minor
one at 4.5 kb (data not shown). In each case, the
blots were rehybridized with an K-tubulin cDNA
probe, to normalize for RNA levels in each lane.
3.2. Mutation analysis
A two-step approach was employed to identify
putative disease-causing mutations in the PCCA
gene in the patients under study. First, we analyzed
¢broblast RNA by DNA sequencing of RT^PCR
products ampli¢ed in seven overlapping fragments
of 350^425 bp which encompass the complete
PCCA coding sequence (Table 1). Second, when in-
formation of genomic structure was available, exonic
fragments were ampli¢ed and sequenced to con¢rm
the presence of the mutations found in the RNA.
Using this approach, a total of ten di¡erent muta-
tions were detected, ¢ve missense, two nonsense and
three splicing defects (Table 2), characterizing ap-
proximately 65% of the total alleles. No prevalent
mutation was found. Mutations I139T, R52W,
1824IVS+3insCT and 1771IVS32del9 were detected
on one allele and the remaining mutations were each
found on two alleles corresponding to homozygous
patients. Mendelian inheritance of the mutations was
con¢rmed by sequencing or by a restriction digestion
test.
The two nonsense mutations (R288X and S537X)
are predicted to result in truncated proteins lacking
functionally important domains. The splicing defects
correspond to two small deletions (1824IVS+3del4
and 1771IVS32del9) and one small insertion
(1824IVS+3insCT), a¡ecting the consensus 5P and
3P splice sites of a 54 bp exon, resulting in exon
skipping, as described elsewhere [14]. The remaining
missense mutations all produce non conservative
amino acid changes distributed along the protein,
with A113T and I139T located near the ATP binding
site and M348K located within the highly conserved
biotin carboxylase domain. The missense mutations
M348K and G606R were screened for but not de-
tected in 50 normal chromosomes. For the remaining
missense mutations, R52W, A113T and I139T, no
Fig. 1. Northern blot analysis of total ¢broblast RNA from
propionic acidemia patients from the pccA complementation
group. Twenty Wg of total RNA was electrophoresed in a form-
aldehyde/agarose gel, transferred to nylon paper and hybridized
with an K cDNA probe. C, control cell line. Lanes 1 to 6, pa-
tients’ cell lines MPS, DFH, ESG, SAG, MSH and JMMO, re-
spectively.
Table 2
Mutations in the PCCA gene identi¢ed in PA patients
Mutation Nucleotide change E¡ect Frequency
No. of alleles (%)
R52Wa 154CCT Arg52Trp 1/20 (5)
A113Ta 337GCA Ala113Thr 1/20 (5)
I139Ta 416TCC Ile139Thr 2/20 (10)
R288X 862CCT Arg288Stop 2/24 (8.4)
M348K 1043TCA Met348Lys 2/24 (8.4)
S537X 1610CCG Ser537Stop 2/24 (8.4)
G606R 1816GCC Gly606Arg 2/24 (8.4)
1824IVS+3del4 1824+3del4 Splicing defect (exon skipping) 2/24 (8.4)
1824IVS+3insCT 1824+3insCT Splicing defect (exon skipping) 1/24 (4.2)
1771IVS32del9 177132del9 Splicing defect (exon skipping) 1/24 (4.2)
Mutations in boldface have not been detected in other populations.
aMutations R52W, A113T and I139T were detected in cDNA, as genomic DNA structure of these regions is lacking. These mutations
could not be screened for in two patients due to lack of ¢broblast samples as source of mRNA.
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screening in the general population could be per-
formed, as information on the genomic structure of
these regions was lacking.
Mutations R52W and R288X, both present on a
CpG dinucleotide, have also been found in Japanese
and Caucasian patients, respectively [18,19]. All the
other mutations have not yet been detected in other
populations.
A neutral polymorphism was also detected, an A
to G transition in nucleotide 552 (GCA/GCG coding
for Ala). In addition, an A to G transition in nucleo-
tide 1348 which causes the substitution of Ile (ATT)
for Val (GTT) was identi¢ed in two patients. To
verify whether this conservative change I450V was
pathogenic or not, we screened 39 control individuals
by restriction analysis of the corresponding exonic
fragment. The variant allele was detected in seven
chromosomes corresponding to a frequency of 9%
(7/78). In the group of pccA-de¢cient patients it
was present in four alleles, corresponding to an over-
all frequency of 16.6% (4/24). One patient carried the
I450V variant and the G606R mutation, both in ho-
mozygous fashion, while in another patient no
change other than I450V was found after sequencing
the complete coding sequence.
3.3. Mitochondrial import and stability of normal and
M348K mutant protein
The cell-free transcription^translation assay of the
human PCCA cDNA cloned in the pGEM vector
yielded a major radioactive product with a molecular
mass of 72 kDa on SDS^PAGE, as predicted for the
precursor K-PCC protein. When this protein product
was incubated with isolated rat liver mitochondria, it
was converted to a lower size form, resistant to di-
gestion with exogenous protease (Fig. 2A), which
demonstrates that the precursor K-PCC protein syn-
thesized in vitro could be imported into mitochon-
dria and cleaved to its mature size, as has been
shown for the rat K-PCC protein [6]. The time course
of mitochondrial uptake showed that after 10 min,
the mature form is already detected and the amount
increases progressively, while the amount of precur-
sor decreases accordingly up to 90 min, when most
of the protein is present in its mature form (Fig. 2B).
To analyze the possible e¡ect of the M348K mu-
tation on K-PCC biogenesis, post-translational mod-
i¢cation or stability, this mutation was introduced by
site-directed mutagenesis in the PCCA cDNA se-
quence cloned in the pGEM vector. In vitro tran-
scription and translation of the mutant cDNA pro-
duced a labeled protein in similar amounts to the
wild-type. The mutant protein was imported into mi-
tochondria and converted into the mature form with
comparable e⁄ciency to the normal protein (data not
shown).
The intramitochondrial stability of the normal and
mutant proteins was investigated by incubation at
37‡C after mitochondrial import over a 24-h period
of time. As shown in Fig. 3, the mutant M348K
protein is degraded more rapidly than the wild-type
protein which is essentially stable up to 24 h. In
contrast, only 70% of the mutant protein is present
at 6 h, and the intensity of the band deceases to
approximately 30% after 24h.
4. Discussion
The aim of this study was to identify new muta-
tions in the PCCA gene in PA patients and to inves-
tigate the possible mechanism by which the muta-
tions a¡ect the protein function. In a ¢rst approach
Fig. 2. In vitro synthesis and mitochondrial import and process-
ing of K-PCC precursor (pK-PCC). The full-length human K-
PCC cDNA was transcribed in vitro, translated in a reticulo-
cyte system in the presence of [35S]methionine^cysteine and in-
cubated with isolated rat liver mitochondria. (A) Products of in
vitro synthesis (lanes 1), supernatant and mitochondrial pellet,
after mitochondrial import (lanes 2 and 3, respectively). An ali-
quot of each sample was incubated with trypsin (+). (B) Time
course of mitochondrial uptake and processing. In vitro synthe-
sized K-PCC precursor was incubated with rat liver mitochon-
dria and aliquots were removed at the indicated times.
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to characterize the molecular basis of the defect,
Northern blot analysis was performed. In contrast
to previously published observations [7,8], seven
PCCA de¢cient patients studied were found to have
normal amounts of K-subunit mRNA (Fig. 1). They
include patients homozygous for M348K, A113T,
R288X, 1824IVS+3del4, a patient with the genotype
1771IVS32del9/R52W, a patient with I139T and a
yet unidenti¢ed mutation on the other allele, and a
patient in whom only the I450V change was detected.
In view of the high genetic heterogeneity found in
this study, with no prevalent PCCA mutations
present, it is probable that the patients studied by
other groups harbor a di¡erent spectrum of muta-
tions which could explain the di¡erences observed
in the Northern blot analysis.
We have identi¢ed ¢ve novel mutations among an
overall spectrum of ¢ve missense, two nonsense and
three splicing mutations detected in the group of pa-
tients under study. The e¡ect of the splicing muta-
tions, causing an in-frame deletion of 18 amino acids
of the mature protein, has been discussed elsewhere
[14]. The disease-causing nature of the nonsense mu-
tations is clear, as the predicted mutant proteins lack
the biotinylation domain present at the carboxyl ter-
minus of the protein [20]. However, the functional
consequences of the missense mutations are not
easily predicted and expression studies are hampered
by the fact that both the K and L subunits of PCC
have to be coexpressed to stabilize the complex and
achieve enzyme activity. In addition, e⁄cient expres-
sion in bacteria could only be achieved with co-over-
expression of chaperonins groES and groEL which
promote the assembly of the PCC subunits [21].
However, all of the amino acid substitutions are
non-conservative and the residues involved are con-
served in related carboxylases from di¡erent organ-
isms. In addition, the pathogenic nature of mutations
M348K and G606R is supported by their absence in
50 alleles from normal individuals.
R52W has also been detected in a Japanese patient
[18], but the presence on a CpG dinucleotide suggests
that it is a recurrent mutation, as PA and other dis-
eases such as phenylketonuria have independent ge-
netic origins in Caucasians and Orientals [11,22].
The I450V change, detected in two homozygous K-
subunit de¢cient PA patients, was found to be
present in 9% of control individuals, indicating that
it is a frequent polymorphic variation. However, the
Ile residue is highly conserved in related carboxylases
from rat, yeast and bacteria and a potential clinical
signi¢cance cannot be de¢nitely ruled out, as this
variant is over represented (16.6%) in K-PCC de¢-
cient patients. Similar ¢ndings of a mutation present
in the general population have been reported in
short-chain acyl-CoA (SCAD) de¢ciency, and the
authors suggested that the variant allele could be a
conditional predisposing allele, that together with
other genetic factors and/or cellular conditions could
cause SCAD and ethylmalonic aciduria [23].
The cell-free in vitro expression analysis of the
M348K mutation has shown that the mutant protein
is markedly more labile than the wild-type, following
import into mitochondria and processing which is
similarly e⁄cient for both proteins. These studies
suggest that the absence of functional K-PCC protein
Fig. 3. Intramitochondrial stability of wild-type and mutant
(M348K) K-PCC at 37‡C. After in vitro synthesis, normal and
mutant K-PCC precursor (pK-PCC) were incubated for 40 min
at 30‡C with rat liver mitochondria. The mitochondria were
then washed twice and resuspended in HMS bu¡er and further
incubated at 37‡C, removing aliquots at di¡erent time points
up to 24 h. Upper panel, SDS^PAGE analysis of wild-type and
mutant (M348K) K-PCC. Lower panel, densitometric scanning
of the gel £uorograms showing the mean þ S.D. from two ex-
periments.The amount of residual mature K-PCC is expressed
in percentages of the amount of imported protein in the sample
after 0 min incubation at 37‡C.
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detectable by [3H]biotin labeling in the patient’s ¢-
broblasts is caused by instability of the mutant pro-
tein inside the mitochondria, being the likely cause of
the disease. Up to now, most of the defects in PCCA
de¢cient patients seemed to directly a¡ect mRNA
stability [7]. In our patients, the presence of normal
quantities of K mRNA indicates a di¡erent e¡ect of
the mutations, as corroborated with the M348K mu-
tation. An increased susceptibility to degradation
could underlie the e¡ects of other missense mutations
in PA, and it appears to be a common disease-caus-
ing mechanism present in many disorders [24,25],
probably related to conformational changes in the
protein. In medium-chain acyl-CoA (MCAD) de¢-
ciency, the amount of stable mutant protein can be
modulated changing the cultivation temperature and
the levels of chaperonins, providing clues to explain
the variable phenotypical manifestations of the dis-
order [26]. In PA, which also shows great clinical and
biochemical heterogeneity, such mechanisms also
need be investigated to analyze possible e¡ects of
the protein quality control system on the phenotypic
expression of unstable mutant proteins.
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